

## APC anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

<b>Catalog# / Size</b>	108411 / 25 µg 108412 / 100 µg
<b>Clone</b>	RB6-8C5
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Gr-1
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Raised against granulocytes of mouse origin
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	<p>Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C<sup>19</sup>. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8<sup>19</sup>. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4<sup>20</sup>.</p> <p>The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes <i>in vivo</i>. Additional reported applications (for relevant formats of this clone) include: <i>in vitro</i> complement-mediated cytotoxicity<sup>2</sup>, <i>in vivo</i> depletion<sup>3-5,9</sup>, immunoprecipitation<sup>1</sup>, immunohistochemical staining<sup>6</sup> (including paraffin-embedded sections<sup>9,16,33-35</sup>, acetone-fixed frozen sections<sup>11</sup> and zinc-fixed sections<sup>15</sup>), and Western blotting<sup>7</sup>. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)<sup>20</sup>.</p> <p><b>Special Note:</b> For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).</p>

### Application References

(PubMed link indicates BioLegend citation)

1. Fleming TJ, *et al.* 1993. *J. Immunol.* 151:2399. (IP)
2. Brummer E, *et al.* 1984. *J. Leukocyte Biol.* 36:505. (CMCD)
3. Stoppacciaro A, *et al.* 1993. *J. Exp. Med.* 178:151. (Deplete)
4. Tumpey TM, *et al.* 1996. *J. Virol.* 70:898. (Deplete)
5. Czuprynski CJ, *et al.* 1994. *J. Immunol.* 152:1836. (Deplete)

6. Nitta H, *et al.* 1997. *Cell Vision* 4:73. (IHC)
7. Jutila MA, *et al.* 1988. *Eur. J. Immunol.* 18:1819. (WB)
8. Engwerda CR, *et al.* 2004. *Am. J. Pathol.* 165:2123.
9. Brown CR, *et al.* 2004. *Infect. Immun.* 72:4956. (Deplete, IHC)
10. Andoniou CE, *et al.* 2005. *Nature Immunology* 6:1011. (FC) [PubMed](#)
11. Li M, *et al.* 2006. *P. Natl. Acad. Sci USA* 103:11736. (IHC)
12. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC) [PubMed](#)
13. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753. (FC) [PubMed](#)
14. Heuser M, *et al.* 2007. *Blood* 110:1639. (FC) [PubMed](#)
15. Wang T, *et al.* 2007. *Infect. Immun.* 75:1144. (IHC)
16. Bosio CM, *et al.* 2007. *J. Immunol.* 178:4538. (IHC)
17. Boehme SA, *et al.* 2009. *Int. Immunol.* 21:81. (IHC)
18. Piao Y, *et al.* 2012. *Neuro Oncol.* 14:1379. [PubMed](#)
19. Ribechini E, *et al.* 2009. *Eur. J. Immunol.* 39:3538.
20. Ma C, *et al.* 2012. *J. Leukoc. Biol.* 92:1199.
21. Li J, *et al.* 2012. *Arthritis Rheum.* 64:1098. [PubMed](#)
22. Fan Q, *et al.* 2014. *Cancer Res.* 74:471. [PubMed](#)
23. Korrer MJ, *et al.* 2014. *PLoS One.* 9:91370. [PubMed](#)
24. Morshed M, *et al.* 2014. *J Immunol.* 192:5314. [PubMed](#)
25. Collins C, *et al.* 2014. *PNAS.* 111:9899. [PubMed](#)
26. Madireddi S, *et al.* 2014. *J Exp Med.* 211:1433. [PubMed](#)
27. Bianchi G, *et al.* 2014. *Cell Death Dis.* 5:1135. [PubMed](#)
28. Guo H, *et al.* 2014. *J Leukoc Biol.* 96:419. [PubMed](#)
29. Roderick JE, *et al.* 2014. *PNAS.* 111:14436. [PubMed](#)
30. Distel E, *et al.* 2014. *Circ Res.* 115:759. [PubMed](#)
31. Iwai H, *et al.* 2015. *Tuberculosis.* 95:246. [PubMed](#)
32. Charmsaz S, *et al.* 2015. *PLoS One.* 10:130692. [PubMed](#)
33. Whiteland J, *et al.* 1994 *J Histochem Cytochem* 43:3 (IHC-P)
34. Brown C, *et al.* 2003 *J Immunology* 171:2 (IHC-P)
35. Obregon-Henao A, *et al.* *PLoS One* 8:11 (IHC-P)

## Product Citations

1. Madireddi S, *et al.* 2014. *J Exp Med.* 211:1433. [PubMed](#)
2. Bianchi G, *et al.* 2014. *Cell Death Dis.* 5:1135. [PubMed](#)
3. Guo H, Cooper S, Friedman A, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0150809. [PubMed](#)
4. Lim H, *et al.* 2016. *Immunol Cell Biol.* 10.1038/icb.2016.72. [PubMed](#)
5. Haimon Z *et al.* 2018. *Nature immunology.* 19(6):636-644 . [PubMed](#)
6. Gan T, *et al.* 2019. *Front Microbiol.* 9:3174. [PubMed](#)
7. Tong CF, *et al.* 2018. *Am J Physiol Cell Physiol.* 315:C409. [PubMed](#)
8. Dzhagalov I, *et al.* 2007. *Blood .* 109:1620. [PubMed](#)
9. Goncalves S, *et al.* 2021. *Cell Reports.* 34(11):108860. [PubMed](#)
10. Kim JS, *et al.* 2020. *Immunity.* 54(1):176-190.e7. [PubMed](#)
11. Garcia-Fabiani MB, *et al.* 2020. *Methods Enzymol.* 632:369. [PubMed](#)
12. Jaiswal AK, *et al.* 2020. *Immunobiology.* 225:151956. [PubMed](#)
13. Kaku H, *et al.* 2014. *J Immunol.* 193:5904. [PubMed](#)
14. Zhou W, *et al.* 2019. *Cell Syst.* 0.597916667. [PubMed](#)
15. Mollaoglu G *et al.* 2018. *Immunity.* 49(4):764-779 . [PubMed](#)
16. Lee S, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
17. Schönberger K, *et al.* 2022. *Cell Stem Cell.* 29:131. [PubMed](#)
18. Qi Z, *et al.* 2022. *Nat Commun.* 13:182. [PubMed](#)
19. Symeonidou V, *et al.* 2021. *Cell Rep.* 37:109900. [PubMed](#)
20. Sharma GP, *et al.* 2021. *PLoS One.* 16:e0259042. [PubMed](#)
21. Ma Q, *et al.* 2021. *Clin Transl Immunology.* 10:e1300. [PubMed](#)
22. Ma C, *et al.* 2012. *J Leukoc Biol.* 92:1199. [PubMed](#)
23. Zhu H, *et al.* 2018. *Elife.* 7:. [PubMed](#)
24. Yu VWC *et al.* 2016. *Cell.* 167(5):1310-1322 . [PubMed](#)
25. Götz P, *et al.* 2022. *Int J Mol Sci.* 23:. [PubMed](#)
26. Yuan Q, *et al.* 2021. *Cell Reports.* 34(5):108724. [PubMed](#)
27. Zhao J, *et al.* 2020. *Pharmacol Res Perspect.* 8:e00660. [PubMed](#)
28. Fan Q, *et al.* 2014. *Cancer Res.* 74:471. [PubMed](#)
29. Han Y, *et al.* 2020. *Nat Commun.* 11:1776. [PubMed](#)
30. Agelidis A, *et al.* 2019. *Front Immunol.* 10:500. [PubMed](#)
31. Sun Y *et al.* 2018. *Cancer cell.* 34(4):643-658 . [PubMed](#)
32. Hinterbrandner M, *et al.* 2021. *JCI Insight.* 6:e151797. [PubMed](#)
33. Gu T, *et al.* 2021. *Front Immunol.* 11:621441. [PubMed](#)
34. Zhao B, *et al.* 2021. *Cell Reports.* 36(3):109401. [PubMed](#)
35. Mann M, *et al.* 2018. *Cell Rep.* 25:2992. [PubMed](#)
36. Fukushima T, *et al.* 2019. *Cell Rep.* 29:4144. [PubMed](#)
37. Mathur S, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
38. Bommireddy R, *et al.* 2020. *Vaccines (Basel).* 8:. [PubMed](#)
39. Perner C, *et al.* 2020. *Immunity.* 53(5):1063-1077.e7. [PubMed](#)
40. Konishi H, *et al.* 2020. *EMBO J.* 39:e104464. [PubMed](#)
41. Vannini N, *et al.* 2019. *Cell Stem Cell.* 24:405. [PubMed](#)
42. Sasaki K, *et al.* 2019. *Nat Commun.* 10:3878. [PubMed](#)
43. Tamura M, *et al.* 2019. *Sci Rep.* 9:8171. [PubMed](#)
44. Gunn BM *et al.* 2018. *Cell host & microbe.* 24(2):221-233 . [PubMed](#)
45. Anastasiou M, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
46. Morshed M, *et al.* 2014. *J Immunol.* 192:5314. [PubMed](#)
47. Distel E, *et al.* 2014. *Circ Res .* 115:759. [PubMed](#)

48. Charmsaz S, *et al.* 2015. PLoS One. 10:130692. [PubMed](#)
49. Jassinskaja M, *et al.* 2021. Cell Reports. 34(12):108894. [PubMed](#)
50. Parada-Kusz M, *et al.* 2018. Dis Model Mech. 11:. [PubMed](#)
51. Zeng J, *et al.* 2019. Cell Rep. 27:549. [PubMed](#)
52. Voisin M, *et al.* 2021. Commun Biol. 4:420. [PubMed](#)
53. Cheng K, *et al.* 2021. Nat Commun. 12:2041. [PubMed](#)
54. Koujah L, *et al.* 2021. Ocul Surf. 21:238. [PubMed](#)
55. Chen D, *et al.* 2020. Cancer Immunol Res. 8:883. [PubMed](#)
56. Bertino P, *et al.* 2019. Oncoimmunology. 8:1601482. [PubMed](#)
57. Lv Z, *et al.* 2020. Oncoimmunology. 9:1747688. [PubMed](#)
58. Hurrell BP, *et al.* 2019. Cell Rep. 29:4509. [PubMed](#)
59. Yu VWC, *et al.* 2017. Cell. 168:944. [PubMed](#)
60. Abraham TS, *et al.* 2019. J Immunol. 202:1301. [PubMed](#)
61. Cong J *et al.* 2018. Cell metabolism. 28(2):243-255. [PubMed](#)
62. Dietmar Herndler-Brandstetter *et al.* 2018. Immunity. 48(4):716-729. [PubMed](#)
63. Niemann J, *et al.* 2019. Nat Commun. 10:3236. [PubMed](#)
64. Xu H, *et al.* 2020. Immunity. 51(4):696-708.e9.. [PubMed](#)
65. Mansell E, *et al.* 2020. Cell Stem Cell. [PubMed](#)
66. Barsoumian HB, *et al.* 2020. J Immunother Cancer. 8:00. [PubMed](#)
67. Mishra BB, *et al.* 2017. Nat Microbiol. 2:17072. [PubMed](#)
68. Kumar MP, *et al.* 2018. Cell Rep. 25:1458. [PubMed](#)
69. Booth CAG, *et al.* 2018. Cancer Cell. 33:274. [PubMed](#)
70. Zhao X, *et al.* 2022. Nat Protoc. 17:2240. [PubMed](#)
71. Zhou H, *et al.* 2022. Oncoimmunology. 11:2057892. [PubMed](#)
72. Kruta M, *et al.* 2021. Cell Stem Cell. [PubMed](#)
73. Zhang H, *et al.* 2019. Mol Cell. 76:110. [PubMed](#)
74. Gironi M, *et al.* 2021. Blood Adv. 5:2817. [PubMed](#)
75. Cho K, *et al.* 2021. iScience. 24:103117. [PubMed](#)
76. Zhu Y, *et al.* 2021. EMBO J. 40:e105320. [PubMed](#)
77. Chen X, *et al.* 2016. PLoS One. 11:e0168861. [PubMed](#)
78. Galle-Treger L, *et al.* 2016. Nat Commun. 7:13202. [PubMed](#)
79. Jonas B, *et al.* 2016. PLoS One. 11: 0159189. [PubMed](#)
80. Guo H, *et al.* 2014. J Leukoc Biol. 96:419. [PubMed](#)
81. Korrer M, Routes J 2014. PLoS One. 9:91370. [PubMed](#)
82. Zhou J, *et al.* 2019. Nat Commun. 10:2427. [PubMed](#)
83. Sydney Lavoie *et al.* 2019. eLife. 8 pii: e39982. [PubMed](#)
84. Galle-Treger L, *et al.* 2020. J Allergy Clin Immunol. 145:502. [PubMed](#)
85. Shafiei-Jahani P, *et al.* 2021. Nat Commun. 12:2526. [PubMed](#)
86. Agelidis A, *et al.* 2021. JCI Insight. 6: [PubMed](#)
87. Yang C, *et al.* 2016. Sci Rep. 6:34643. [PubMed](#)
88. Gao Y, *et al.* 2020. Immunity. 52(6):1007-1021.e8. [PubMed](#)
89. Subramanian K, *et al.* 2019. Nat Microbiol. 4:62. [PubMed](#)
90. Xu Q, *et al.* 2021. Theranostics. 11:1937. [PubMed](#)
91. Xiao Y, *et al.* 2022. Nat Commun. 13:758. [PubMed](#)
92. Guan X, *et al.* 2022. Nat Commun. 13:2834. [PubMed](#)
93. Chen R, *et al.* 2021. Cell Reports. 34(7):108751. [PubMed](#)
94. Ouyang L, *et al.* 2016. Sci Rep. 6:39541. [PubMed](#)
95. Lu W, *et al.* 2016. PLoS One. 11: 0149543. [PubMed](#)
96. Winchell CG, *et al.* 2020. Front Immunol. 11:077083333. [PubMed](#)
97. Yu JM, *et al.* 2019. Nat Commun. 4:388888889. [PubMed](#)
98. Okwan-Duodu D, *et al.* 2018. Arterioscler Thromb Vasc Biol. 38:1125. [PubMed](#)
99. Metidji A *et al.* 2018. Immunity. 49(2):353-362. [PubMed](#)
100. Matsumura T, *et al.* 2022. Nat Commun. 13:7064. [PubMed](#)
101. Ha TC, *et al.* 2020. Hum Gene Ther. 32:458. [PubMed](#)
102. Kandasamy M, *et al.* 2013. PLoS Pathog. 9:e1003115. [PubMed](#)
103. Richardson ET, *et al.* 2015. PLoS One. 10: 1371. [PubMed](#)
104. Ruscher R, *et al.* 2018. Bio Protoc. 8:e2757. [PubMed](#)
105. Wang T *et al.* 2018. Immunity. 49(3):504-514. [PubMed](#)
106. Ovadya Y, *et al.* 2018. Nat Commun. 9:5435. [PubMed](#)
107. Di Genua C, *et al.* 2019. Haematologica. 104:2215. [PubMed](#)
108. Siddique SM, *et al.* 2019. Sci Rep. 9:13977. [PubMed](#)
109. Resch TK, *et al.* 2018. Sci Rep. 0.722916667. [PubMed](#)
110. Pattabiraman D, *et al.* 2009. Mol Cancer Res. 1.317361111. [PubMed](#)
111. Tuong ZK, *et al.* 2021. Cell Rep. 37:110132. [PubMed](#)
112. Mairhofer D, *et al.* 2015. J Invest Dermatol. 135: 2785-93. [PubMed](#)
113. Roderick J, *et al.* 2014. Proc Natl Acad Sci U S A. 111:14436. [PubMed](#)
114. Namkoong H, *et al.* 2018. PLoS Pathog. 14:e1006955. [PubMed](#)
115. Skucha A, *et al.* 2018. Nat Commun. 9:1983. [PubMed](#)
116. Li Q, *et al.* 2022. Front Oncol. 12:841977. [PubMed](#)
117. Zhou H, *et al.* 2021. Cell Death Discov. 7:332. [PubMed](#)
118. Hu R, *et al.* 2015. J Immunol. 195: 4802 - 4809. [PubMed](#)
119. Asada S, *et al.* 2018. Nat Commun. 9:2733. [PubMed](#)
120. Weckbach LT, *et al.* 2019. J Exp Med. 216:350. [PubMed](#)
121. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
122. Nguyen GT, *et al.* 2020. eLife. 9:e56656.. [PubMed](#)
123. Matsumoto M, *et al.* 2008. J Immunol. 181:3628. [PubMed](#)
124. Yang N, *et al.* 2022. Nat Commun. 13:2336. [PubMed](#)
125. Iwai H, *et al.* 2015. Tuberculosis (Edinb). 95:246. [PubMed](#)
126. Qiu X, *et al.* 2009. Infect Immun. 77:85. [PubMed](#)
127. Hidalgo San Jose L, *et al.* 2020. Cell Rep. 30:69. [PubMed](#)

128. Barsoumian HB, *et al.* 2022. *Cancers (Basel)*. 14: PubMed
129. Fielding C, *et al.* 2022. *Nat Commun*. 13:543. PubMed
130. Kurashima Y, *et al.* 2021. *Nat Commun*. 12:1067. PubMed
131. Li J, *et al.* 2012. *Arthritis Rheum*. 64:1098. PubMed
132. Collins C, *et al.* 2014. *Proc Natl Acad Sci U S A*. 111:9899. PubMed
133. Hussein M, *et al.* 2015. *PLoS One*. 10: 0135218. PubMed
134. Vannini N, *et al.* 2016. *Nat Commun*. 7:13125. PubMed
135. Stone S *et al.* 2018. *Glia*. 66(7):1331-1345. PubMed
136. Henkle TR, *et al.* 2021. *Cancer Res*. 81:4560. PubMed
137. Zeng F, *et al.* 2021. *J Invest Dermatol*. 596:141. PubMed
138. Guo S, *et al.* 2021. *Frontiers in Immunology*. 11:614667. PubMed
139. Cabal-Hierro L, *et al.* 2020. *Nat Commun*. 11:1406. PubMed
140. Omenetti S, *et al.* 2019. *Immunity*. 51:77. PubMed
141. Wang X, *et al.* 2018. *Front Immunol*. 9:2615. PubMed
142. Riopel M, *et al.* 2019. *Mol Metab*. 20:89. PubMed
143. Schmidts A, *et al.* 2020. *J Immunother Cancer*. 8: PubMed
144. Wang Y, *et al.* 2022. *Nat Cell Biol*. 24:230. PubMed
145. Zhang J, *et al.* 2021. *Stem Cell Res Ther*. 12:579. PubMed
146. Ren X, *et al.* 2021. *Cell Death Dis*. 12:484. PubMed

**RRID** AB\_313376 (BioLegend Cat. No. 108411)  
 AB\_313377 (BioLegend Cat. No. 108412)

## Antigen Details

---

<b>Structure</b>	21-25 kD
<b>Distribution</b>	Granulocytes, monocytes
<b>Cell Type</b>	Granulocytes, Monocytes, Neutrophils
<b>Biology Area</b>	Immunology, Innate Immunity
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Fleming TJ, <i>et al.</i> 1993. <i>J. Immunol</i>. 151:2399.</li> <li>2. Jutila MA, <i>et al.</i> 1988. <i>Eur. J. Immunol</i>. 18:1819.</li> <li>3. Goni O, <i>et al.</i> 2002. <i>Int. Immunol</i>. 14:1125.</li> </ol>
<b>Gene ID</b>	<a href="#">17067</a> <a href="#">546644</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---

APC anti-mouse Ly-6G/Ly-6C (Gr-1), Biotin anti-mouse Ly-6G/Ly-6C (Gr-1), FITC anti-mouse Ly-6G/Ly-6C (Gr-1), PE anti-mouse Ly-6G/Ly-6C (Gr-1), PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1), Purified anti-mouse Ly-6G/Ly-6C (Gr-1), PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1), Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1), Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1), Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1), Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1), APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1), Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1), PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1), PerCP anti-mouse Ly-6G/Ly-6C (Gr-1), Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1), Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1), Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1), Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1), Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1), Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1), Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1), Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1), APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1), TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1), TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1), TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1), Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1), APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1), Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody, Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1)

## Product Data

---



C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C APC (clone RB6-8C5, filled histogram) or APC Rat IgG2b,  $\kappa$  isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587